We previously demonstrated that additional FX also enhances coagulation potential in the presence of emicizumab [17], indicating that FX, in combination with various nonfactor therapies, would contribute to effective management of people with hemophilia in difficult clinical circumstances. This evidence concerns the gene F10 and hemophilia.